IGF-1 LR3 vs Thymalin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Thymalin
Thymalin is a polypeptide preparation derived from calf thymus. Developed in Russia, it has been used for decades to support immune function and has shown potential anti-aging effects in long-term studies.
Full details →Side-by-Side Comparison
| Aspect | IGF-1 LR3 | Thymalin |
|---|---|---|
| Mechanism | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. | Regulates the ratio of T-cell subpopulations, stimulates cellular immunity, and enhances phagocytosis. Also affects neuroendocrine regulation and may influence melatonin production. |
| Typical Dosage | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. | Clinical protocols: 5-20mg daily intramuscularly for 3-10 days. Often cycled 1-2 times per year for maintenance. |
| Administration | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. | Intramuscular injection. Usually administered in short courses rather than continuously. Often combined with Epithalamin for anti-aging protocols. |
| Side Effects | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. | Generally well-tolerated. May cause injection site reactions or temporary flu-like symptoms as immune function is modulated. |
| Best For |